RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Evaluation of amide bioisosteres leading to 1,2,3-triazole containing compounds as GPR88 agonists
Design, synthesis, and structure-activity relationship studies
Rahman, M. T., Decker, A. M., Laudermilk, L., Maitra, R., Ma, W., Ben Hamida, S., Darcq, E., Kieffer, B. L., & Jin, C. (2021). Evaluation of amide bioisosteres leading to 1,2,3-triazole containing compounds as GPR88 agonists: Design, synthesis, and structure-activity relationship studies. Journal of Medicinal Chemistry, 64(16), 12397-12413. https://doi.org/10.1021/acs.jmedchem.1c01075, https://doi.org/10.1021/acs.jmedchem.1c01075
The orphan receptor GPR88 has been implicated in a number of striatal-associated disorders, yet its endogenous ligand has not been discovered. We have previously reported that the amine functionality in the 2-AMPP-derived GPR88 agonists can be replaced with an amide (e.g., 4) without losing activity. Later, we have found that the amide can be replaced with a bioisosteric 1,3,4-oxadiazole with improved potency. Here, we report a further study of amide bioisosteric replacement with a variety of azoles containing three heteroatoms, followed by a focused structure-activity relationship study, leading to the discovery of a series of novel 1,4-disubstituted 1H-1,2,3-triazoles as GPR88 agonists. Collectively, our medicinal chemistry efforts have resulted in a potent, efficacious, and brain-penetrant GPR88 agonist 53 (cAMP EC50 = 14 nM), which is a suitable probe to study GPR88 functions in the brain.
